Ordopidine

Drug Profile

Ordopidine

Alternative Names: ACR-325

Latest Information Update: 03 Jun 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Carlsson Research AB; NeuroSearch Sweden AB
  • Developer Saniona
  • Class Antidepressants; Antimanics; Fluorobenzenes; Piperidines; Sulfones
  • Mechanism of Action Adrenergic receptor modulators; Dopamine release modulators; Glutamate agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bipolar disorders; Parkinson's disease

Most Recent Events

  • 31 May 2016 Phase-I clinical trials in Bipolar disorders in Sweden (PO)
  • 31 May 2016 Phase-I clinical trials in Parkinson's disease in Germany (PO)
  • 31 May 2016 Phase-I clinical trials in Parkinson's disease in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top